XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 25.60

-0.4%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: aknahow who wrote (5134)	12/18/1997 8:45:00 AM
From: Robert K.	Read Replies (2) of 17367

At least 2 presentations. Some heavy hitters there. This presentation and wording peaks my interest even more...... .2:45 Antifungal Peptides Derived from Bactericidal/Permeability-Increasing Protein: Preclinical Research Summary Roger G. Little, PhD, Director, Biochemistry Department, XOMA Corporation While elucidating BPI's structure and function, we have discovered that peptides from a particular region (amino acids 142-169) within BPI had unexpectedly potent activity against Candida albicans. Utilizing an iterative synthesis/screening process, the initial activity has been amplified into a series of peptides characterized by: fungicidal activity against a broad range of fungal genera in vivo antifungal activity in mortality and target organ CFU analysis fungicidal activity against polyene- and azole-resistant Candida albicans Currently, lead compounds have been prioritized based on in vivo efficacy in murine systemic candidiasis and aspergillosis models and on in vitro fungicidal activity. (nothing we dont know but..............)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next